Engineers Developed New Method to Reprogram Immune Cells
MIT researchers created a lipid nanoparticle technique to reprogram natural killer cells directly within the body.
Updated on Oct. 13, 2026 in Cancer
Live Poll
Should medical research prioritize developing in-body cell reprogramming to lower healthcare costs and improve accessibility?
MIT engineers have developed a new technique using lipid nanoparticles to reprogram natural killer (NK) cells inside a patient's body. This method aims to streamline the treatment process by eliminating the need to manufacture engineered immune cells outside of the patient.
Why it matters
The approach seeks to bypass the significant time and expense associated with current CAR T cell therapies. By reprogramming cells in vivo, researchers hope to provide a more efficient path for treating various cancers and autoimmune disorders.
In a study of mice, 80 percent of NK cells were successfully reprogrammed, with three of five melanoma-stricken mice entering complete remission. Treatment required five injections for T cell lymphoma and only one injection for autoimmune hepatitis.
The players
MIT
The Massachusetts Institute of Technology is a private research university located in Cambridge, Massachusetts, widely known for its work in science, engineering, and technology.
U.S. Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices.
Sanofi
This global healthcare company focuses on the research, development, and manufacturing of innovative therapeutic solutions and vaccines.
The details
Lipid nanoparticles are coated with antibody fragments that bind to receptors on the surfaces of NK cells, delivering mRNA that encodes chimeric antigen receptors. Once inside, these modified cells are directed to identify and eliminate dysfunctional T cells or cancer cells.
Timeline
The research study was published in Nature Biotechnology on October 13, 2026.
Health Landscape
This technique marks a departure from the seven FDA-approved CAR T cancer treatments by shifting the manufacturing process from the laboratory to inside the patient. This shift represents a broader effort to reduce the complexity and costs associated with existing cellular immunotherapies.
If clinical trials prove successful, this technology could eventually offer patients a faster, less expensive alternative to traditional cell-based therapies. It may also expand treatment options for conditions such as multiple sclerosis and rheumatoid arthritis.
The takeaway
This breakthrough offers a potential paradigm shift in how we treat complex diseases by turning a patient's own immune system into a drug factory. Future development could make highly specialized immunotherapy far more accessible to the general public.
Further reading
Learn more about the latest research in this field at the Cancer section.
Live Poll
Should medical research prioritize developing in-body cell reprogramming to lower healthcare costs and improve accessibility?
